

REPORT FOR RELEASE

Meeting of 19-20 April 2007

CMD(v) agreed on recommended clock start dates for the period November 2007 – September 2008.

Applicants are advised to follow these dates, in order to facilitate smooth conduct of the mutual recognition procedure and the second phase of the decentralised procedure. The dates established are: 1 November 2007, 29 November 2007, 27 December 2007, 31 January 2008, 28 February 2008, 3 April 2008, 1 May 2008, 3 July 2008, 31 July 2008, 28 August 2008 and 25 September 2008. A comprehensive list of start dates and other mile stone dates in the 90 day procedure has been published on http://www.hma.eu/uploads/media/CMDv_GUI-005-01_Clock_Start_Dates.pdf

New member

The responsibility for the licensing of veterinary medicinal products has moved in Portugal from the National Institute for Pharmacy and Medicines (Infarmed) to the Veterinary Directorate (DGV) of the Ministry of Agriculture. For this reason a new CMD(v) member was appointed by Portugal. Maria Mendes from DGV succeeded Margarida Alves from Infarmed.

Product discussion

Four products reached day 78 of the mutual recognition procedure in April 2007, out of which 2 were discussed.

	MRP	DCP	Referrals
<i>Procedures</i>	4	0	0
Products	4	0	0
Immunological	0	0	0
Pharmaceutical	4	0	0
Discussed	2	0	0

It was noted that following the March meeting agreement was reached on all 7 products by the end of the mutual recognition or decentralised procedure.

Meeting with interested parties

A delegation of CMD(v) members, the CMD(v) chair and representatives from IFAH-Europe, EGGVP and the Association of Veterinary Consultants (AVC) met to discuss issues of mutual interest. It was the first time for AVC to participate. The topics addressed included:

- the number of MRP, DCP and referrals;
- the progress with the annual survey on MRP, DCP and referrals;
- the development of a joint action plan for packaging issues;
- labelling of diluents;
- the acceptance of generics where indications, target species or withdrawal periods differ from those authorised in the concerned member state.

Information

CMD(v) documents, including the annual report 2006, are available on www.hma.eu.

For further information, please contact the secretariat at the European Medicines Agency, for the attention of Wim Riepma, 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
wim.riepma@emea.europa.eu